Biodistribution and dosimetry study of i‐rh‐annexin v in mice and humans

Nuclear Medicine Communications

Volumn 24, Issue 8, 2003, Pages 871-880

  Lahorte, C M M ^a   Van de wiele, C ^a   Bacher, K ^a   Van den bossche, B ^a   Thierens, H ^a   Van belle, S ^a   Slegers, G ^a   Dierckx, R A ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Annexin V; Apoptosis; Programmed cell death; SPECT

Indexed keywords

DIAGNOSTIC AGENT; LIPOCORTIN 5; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT;

ADULT; ANIMAL; ANTIBODY SPECIFICITY; APOPTOSIS; ARTICLE; BODY BURDEN; CLINICAL TRIAL; COMPARATIVE STUDY; FEMALE; HUMAN; ISOTOPE LABELING; MALE; METABOLIC CLEARANCE RATE; METHODOLOGY; MIDDLE AGED; MOUSE; PHYSIOLOGY; RADIATION DOSE; RADIOMETRY; SPECIES DIFFERENCE; TISSUE DISTRIBUTION; WHOLE BODY COUNTING;

ADULT; ANIMALS; ANNEXIN A5; APOPTOSIS; BODY BURDEN; FEMALE; HUMANS; IODINE RADIOISOTOPES; ISOTOPE LABELING; MALE; METABOLIC CLEARANCE RATE; MICE; MIDDLE AGED; ORGAN SPECIFICITY; RADIATION DOSAGE; RADIOMETRY; RADIOPHARMACEUTICALS; SPECIES SPECIFICITY; TISSUE DISTRIBUTION; WHOLE-BODY COUNTING;

EID: 1842521917     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/01.mnm.0000084585.29433.58     Document Type: Article

References (39)

1. White E. Life, death and the pursuit of apoptosis. Gene Dev 1996; 10: 1-15.
2. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998; 281: 1305-1308.
3. Evan G, Littlewood T. Apoptosis: A matter of life and cell death. Science 1998; 281: 1317-1321.
4. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998; 281: 1309-1312.
5. Thornberry NA, Lazebnik Y. Caspases: Ennemies within. Science 1998; 281: 1312-1316.
6. Dive C, Hickman JA. Drug-target interactions: only the first step in the commitment to a programmed cell death? Br J Cancer 1991; 64: 192-196.
7. Green AM, Steinmetz ND. Monitoring apoptosis in real time. Cancer J 2002; 8: 82-92.
8. 99mTc recombinant human annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis. Clin Canc Res 2002; 8: 2766-2774.
9. Blankenberg FG, Narula J, Strauss HW. In vivo detection of apoptotic cell death: A necessary measurement for evaluating therapy for myocarditis, ischemia and heart failure. J Nucl Cardiol 1999; 6: 531-539.
10. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis: Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using a fluorescein labelled annexin V. J Immunol Methods 1995; 184: 39-51.
11. Blankenberg FG, Tait JF, Strauss HW. Apoptotic cell death: its implications for imaging in the next millenium. Eur J Nucl Med 2000; 27: 359-367.
12. Blankenberg FG, Ohtsuki K, Strauss HW. Dying a thousand deaths: Radionuclide imaging of apoptosis. Q J Nucl Med 1999; 43: 170-176.
13. Hofstra L, Liem IH, Dumont EA, et al. Visualisation of cell death in vivo in patients with acute myocardial infarction. Lancet 2000; 356: 209-212.
14. Hofstra L, Dumont EA, Thimister PWL, et al. In vivo detection of apoptosis in an intracardiac tumor. JAMA 2001; 285: 1841-1842.
15. Stratton JR, Dewhurst TA, Kasina S, et al. Selective uptake of radiolabeled annexin V on acute porcine left atrial thrombi. Circulation 1995; 92: 3113-3121.
16. Thiagarajan P, Tait JF. Binding of annexin V/placental anticoagulant protein I to platelets. J Biol Chem 1990; 265: 17420-17423.
17. Bevers EM, Comfurius P, Zwaal RFA. Changes in membrane phospholipid distribution during platelet activation. Biochim Biophys Acta 1983; 736: 57-66.
18. Stuart MCA, Bevers EM, Comfurius P, Zwaal RFA, Reutelingsperger CPM, Frederik PM. Ultrastuctural detection of surface exposed phosphatidylserine on activated blood platelets. Thromb Hemostas 1995; 74: 1145-1151.
19. Funakoshi T, Heimark RL, Hendrickson LE, McMullen BA, Fujikawa K. Human placental anticoagulant protein: isolation and characterisation. Biochemistry 1987; 26: 5572-5578.
20. Tait JF, Sakata M, McMullen BA, et al. Placental anticoagulant proteins: isolation and comparative characterisation of four members of the lipocortin family. Biochemistry 1998; 27: 6268-6276.
21. Wood BL, Gibson DF, Tait JF. Increased erythrocyte phosphatidylserine exposure in sickle cell disease: flowcytometric measurement and clinical associations. Blood 1996; 88: 1873-1880.
22. Tait JF, Engelhardt S, Smith C, Fujikawa K. Prourokinaseannexin V chimeras. J Biol Chem 1995; 270: 21594-21599.
23. Thiagarajan P, Benedict CR. Inhibition of arterial thrombosis by recombinant annexin V in a rabbit carotid artery injury model. Circulation 1997; 96: 2339-2347.
24. 123I-labelled annexin V: A potential agent for SPECT imaging of apoptotic cells. J Labelled Compounds and Radiopharmaceuti-cals 2000; 43: 739-751.
25. 123I-labelled human recombinant annexin V. Biomol Eng 2001; 17: 51-53.
26. 123I-annexin V is increased in septic rats. J Labelled Compounds and Radiopharmaceuticals 2001; 44(suppl 1): S430-S432.
27. Behr TM, Becker GM, Béhé M. Radioiodination of monoclonal antibodies, proteins and peptides for diagnosis and therapy. A review of standardized, reliable and safe procedures for clinical grade levels of kBq to GBq in the Göttingen/Marburg experience. Nuklearmedizin 2001; 41: 71-79.
28. Loevinger R, Budinger T, Watson E. MIRD primer for absorbed dose calculations. Revised edition. New York: The Society of Nuclear Medicine, 1991.
29. Cristy M, Eckerman K. Specific absorbed fractions of energy at various ages from internal photon sources. ORNL/TM-8381/VII. Oak Ridge, TN: Oak Ridge National Laboratory, 1987: 7-29.
30. Stabin MG. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 1996; 37: 538-546.
31. International Commission on Radiological Protection. 1990 recommendations of the International Commission on Radiological Protection. ICRP Publication 60. Ann ICRP 1991; 21(1-3): 6-10. Oxford: Pergamon Press.
32. Beekhuis H. Population radiation absorbed dose from nuclear medicine procedures in the Netherlands. Health Phys 1988; 54: 287-291.
33. World Health Organization. Use of ionizing radiation and radionuclides on human beings from medical research, training, and non-medical purposes. Report of a WHO expert Committee. WHO Technical Report Series 611. Geneva: WHO, 1977.
34. International Commission on Radiological Protection. Radiological protection in biomedical research. ICRP Publication 62. Ann ICRP 1991; 22: 12-13. Oxford: Pergamon Press.
35. 99mTc-annexin. J Nucl Med 2001; 42: 382-387.
36. 99mTc-BTAP-annexin-V in humans. Eur J Nucl Med 2001; 28: 1373-1378.
37. 99mTechnetium labeled annexin V. Am J Transplant 2001; 1: 270-277.
38. 99mTc-Hynexin, a novel rh-annexin V radiopharmaceutical. J Nucl Med 2002; 43(5, suppl): 70P-71P.
39. Steinmetz ND, Green AM, Sparks RB, Vanderheyden JL. Safety, tolerability, biodistribution, and radiation dosimetry of Tc-99m-hynic-Annexin V in healthy human volunteers. Eur J Nucl Med 2002; 29(suppl 1): S49.